Loading
Latest filing published 03 Jan 2022 for Adial Pharmaceuticals, INC., €23k.
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
This profile gathers the share dealings of James W. Newman Jr. in Adial Pharmaceuticals, Inc., where the filings describe the role as board member. We count 16 filings; the first trade dates from 31 July 2018 and the latest from 30 December 2021.
No open-market sale appears; the market trades are 9 purchases worth €109k. The totals exclude 2 filings filed without an amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 2 share grants. So far in 2022, the count stands at 3 purchases and no sales.
A typical purchase (the median) is worth €12k. Of 7 purchases, 5 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.
Most recently, on 3 January 2022, the filings show an open-market purchase worth €12k in Adial Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations